secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001104659-23-038299
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.03, 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron amends $720M lease financing to align covenants with Dec 2022 credit agreement
--------------------------------------------------------------------------------

- Third A&R Participation Agreement aligns financial and operating covenants with credit agreement entered December 2022.
- $720 million lease financing for corporate headquarters; maturity remains March 2027 with 5-year extension option.
- Yield on advances unchanged, based on 1-month SOFR term rate plus spread and margin tied to debt rating/leverage.
- No new borrowing; amendment and restatement of existing facility; lease term extended previously to 2027.
- Regeneron guarantees obligations; subsidiary guarantors only join if they have borrowings under the credit agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465923038299/0001104659-23-038299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465923038299/tm2310647d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-038299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer